Rapid, Sensitive, and Reliable: EBV Diagnostic Kit Redefines the “Kissing Disease” Testing Landscape
Sansure is a prominent in vitro diagnostic solution provider, integrating cutting-edge diagnostic reagents, instruments, and independent clinical laboratory services. At the core of the company’s innovation is its commitment to advancing genetic technology. Sansure is a National Demonstration Centre for the Application of Genetic Testing Technology and a National Joint Local Engineering Research Center for Genetic Diagnosis of Infection Diseases and Tumours.
Transforming EBV Screening with Advanced Technologies
Sansure has developed a series of internationally leading core technologies and over 500 products that exceed the advanced level both domestically and globally. These new technologies and products have allowed the company to bridge the gap with international standards, breaking the monopoly of imports and promoting the application of gene technology from specialized departments to a wide range of medical institutions, from high-end laboratories in large hospitals to all levels of healthcare facilities.
Sansure’s Solution for Infectious Mononucleosis (Mono)
Infectious mononucleosis, or “mono,” is a highly contagious illness typically caused by the Epstein-Barr virus (EBV). The virus spreads easily through bodily fluids, earning mono the nickname “kissing disease.” caused by a kissing virus. Sansure’s EBV DNA Quantitative Fluorescence Diagnostic Kit has emerged as one of the best solutions for accurate EBV screening and monitoring drug efficacy.
Innovative Technologies for Unparalleled Performance
Sansure’s kit leverages several cutting-edge technologies to deliver exceptional performance. The “Advanced Magnetic Beads Technology” ensures simple sample preparation and high-purity nucleic acid extraction, enabling highly sensitive and reproducible PCR assays. The “One-Tube Fast Release Technology” allows for rapid lysis of pathogens at room temperature, streamlining the extraction process and enabling EBV screening beyond specialized laboratories. Moreover, the “Multiplex Fluorescent PCR Amplification Technology” delivers rapid and accurate identification of EBV, with an amplification time of just 70 minutes. Sensitivity is also impressive, reaching 400 copies/mL.
Conclusion
Sansure has emerged as a leading force in the field of in vitro diagnostics, driven by its unwavering commitment to advancing genetic technology. Through its extensive portfolio of over 500 cutting-edge products, the company has bridged the gap with international standards and broken the monopoly of imported diagnostic solutions.
